ES2067720T3 - Composicion y metodo para el tratamiento de la osteoporosis en mamiferos. - Google Patents

Composicion y metodo para el tratamiento de la osteoporosis en mamiferos.

Info

Publication number
ES2067720T3
ES2067720T3 ES90811032T ES90811032T ES2067720T3 ES 2067720 T3 ES2067720 T3 ES 2067720T3 ES 90811032 T ES90811032 T ES 90811032T ES 90811032 T ES90811032 T ES 90811032T ES 2067720 T3 ES2067720 T3 ES 2067720T3
Authority
ES
Spain
Prior art keywords
osteoporosis
mammals
treatment
composition
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90811032T
Other languages
English (en)
Inventor
Robert R Dr Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2067720T3 publication Critical patent/ES2067720T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN PREPARADO PARA EL TRATAMIENTO DE LA OSTEOPOROSIS EN LOS MAMIFEROS COMPRENDIENDO FACTOR 1 GROWTH INSULINICO (IGF-1) Y METODO PARA SU APLICACION.
ES90811032T 1990-01-03 1990-12-27 Composicion y metodo para el tratamiento de la osteoporosis en mamiferos. Expired - Lifetime ES2067720T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46041690A 1990-01-03 1990-01-03

Publications (1)

Publication Number Publication Date
ES2067720T3 true ES2067720T3 (es) 1995-04-01

Family

ID=23828617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90811032T Expired - Lifetime ES2067720T3 (es) 1990-01-03 1990-12-27 Composicion y metodo para el tratamiento de la osteoporosis en mamiferos.

Country Status (15)

Country Link
US (2) US5646116A (es)
EP (1) EP0436469B1 (es)
JP (1) JP3053116B2 (es)
KR (1) KR100200995B1 (es)
AT (1) ATE118172T1 (es)
AU (1) AU629443B2 (es)
CA (1) CA2033469C (es)
DE (1) DE69016768T2 (es)
DK (1) DK0436469T3 (es)
ES (1) ES2067720T3 (es)
GR (1) GR3015490T3 (es)
IE (1) IE66240B1 (es)
IL (1) IL96841A (es)
NZ (1) NZ236618A (es)
ZA (1) ZA916B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133087T2 (de) * 1990-05-30 2003-04-03 Institute Of Molecular Biology Inc., Boston Kombination aus IGF-I und TGF-beta zur Knochenregenerierung
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
TW267102B (es) * 1992-03-13 1996-01-01 Ciba Geigy
JPH08500123A (ja) * 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
WO1996002565A1 (en) * 1994-07-20 1996-02-01 Celtrix Pharmaceuticals, Inc. Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1996007744A1 (en) * 1994-09-08 1996-03-14 Chiron Corporation A method of improved production of insulin-like growth factor
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US7026292B1 (en) 1995-12-12 2006-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
JP2000512274A (ja) * 1996-05-31 2000-09-19 ノボ ノルディスク アクティ―ゼルスカブ 骨粗しょう症の周期的（整合性）治療における成長ホルモン成分及び骨抗吸収剤
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6627746B1 (en) 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US6846496B1 (en) * 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
AU4935701A (en) 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US7189233B2 (en) * 2001-10-22 2007-03-13 Surgrx, Inc. Electrosurgical instrument
US7812120B2 (en) 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
JPWO2005002590A1 (ja) * 2003-07-01 2006-08-10 アステラス製薬株式会社 骨量増加誘導剤
US20050171015A1 (en) * 2003-10-31 2005-08-04 Crabtree Gerald R. Methods and agents for enhancing bone formation or preventing bone loss
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
WO2014143992A1 (en) * 2013-03-15 2014-09-18 University Of Rochester Treating lysosomal storage disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95236T1 (de) * 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
ATE112684T1 (de) * 1987-04-28 1994-10-15 Boehringer Mannheim Gmbh Verwendung von igf-ii zur behandlung von knochenkrankheiten.
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
IL88344A (en) * 1987-11-12 1994-06-24 Schering Corp Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages

Also Published As

Publication number Publication date
IL96841A (en) 1996-05-14
IE910004A1 (en) 1991-07-17
AU629443B2 (en) 1992-10-01
GR3015490T3 (en) 1995-06-30
IE66240B1 (en) 1995-12-13
US5646116A (en) 1997-07-08
CA2033469C (en) 2003-01-28
ZA916B (en) 1991-08-28
KR100200995B1 (ko) 1999-06-15
IL96841A0 (en) 1991-09-16
KR910021243A (ko) 1991-12-20
US6174857B1 (en) 2001-01-16
CA2033469A1 (en) 1991-07-04
JPH04235135A (ja) 1992-08-24
EP0436469B1 (en) 1995-02-08
DE69016768T2 (de) 1995-06-14
JP3053116B2 (ja) 2000-06-19
AU6853290A (en) 1991-07-04
EP0436469A1 (en) 1991-07-10
ATE118172T1 (de) 1995-02-15
NZ236618A (en) 1997-06-24
DK0436469T3 (da) 1995-04-03
DE69016768D1 (de) 1995-03-23

Similar Documents

Publication Publication Date Title
ZA916B (en) Composition and method for the treatment of osteoporosis in mammals
ES2142380T3 (es) Hormona paratiroide y raloxifeno para el aumento de la masa osea.
ES2140463T3 (es) Prevencion y tratamiento de la neuropatia periferica.
NZ220894A (en) Peptides of various lengths (37-730 aa) having osteoinductive effects
EP0552240A4 (en) New method of treating depression
EP0607252A4 (en) Method of treating hiv infection.
ATE158147T1 (de) Verfahren zur herstellung von galacto- olichosacchariden und diese enthaltende viefutter
ES2071080T3 (es) Igf-i para tratar el efecto adverso de la terapia con esteroides.
ES2144527T3 (es) Metodo para el tratamiento de disfunciones en la reproduccion.
NZ247406A (en) Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3
EP0515434A4 (en) Method for treating intestinal diseases
ATE132750T1 (de) Behandlung von intraokularem druck mit einer synergischen kombination
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE3866773D1 (de) Verfahren zur herstellung von acetylenepoxiden und deren verwendung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 436469

Country of ref document: ES